CytoMed Therapeutics Limited (GDTC) Expected Move

Expected move estimates the probable price range for a given period based on at-the-money options pricing. It reflects the market consensus for volatility over the selected timeframe.

CytoMed Therapeutics Limited (GDTC) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $14.2M, listed on NASDAQ, employing roughly 43 people, carrying a beta of -0.17 to the broader market. CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. Led by Chee Kong Choo, public since 2023-04-14.

Expected move analysis estimates the probable price range implied by options pricing. No recent options activity for GDTC as of 2026-06-01; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how expected move is reported and how to read the data →